Brief: Imricor Medical Systems Says Anticipated FDA Clearances Of Additional Capital Equipment Expected To Broaden Product Offering Available To U.S. Customers
10/08/2026 02:12
BRIEF-Imricor Medical Systems Says Anticipated FDA Clearances Of Additional Capital Equipment Expected To Broaden Product Offering Available To U.S. Customers Aug 10 (Reuters) - Imricor Medical Systems, Inc IMR.AX:
ANTICIPATED FDA CLEARANCES OF ADDITIONAL CAPITAL EQUIPMENT EXPECTED TO BROADEN PRODUCT OFFERING AVAILABLE TO U.S. CUSTOMERS
Further company coverage: IMR.AX
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Imricor Medical Systems
See all newsBrief: Imricor Medical Systems Says FDA Completes Review Of Imricor's Third PMA Module
Brief: Imricor Medical Systems Says FDA Accepts Imricor Pma Manufacturing Module
Brief: Imricor Medical Systems Says Anticipated FDA Clearances Of Additional Capital Equipment Expected To Broaden Product Offering Available To U.S. Customers
Imricor Medical Systems hits 3-month high on securing first US hospital customer
Brief: Imricor Medical Systems, Receives FDA 510(K) Clearance For Northstar Pediatric Label Expansion